1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97:1262–1271.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349:1793–1802.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012; 30:718–721.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381:805–816.
5. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31:5.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016; 375:209–219.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017; 377:1836–1846.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018; 110:110.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019; 37:423–438.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005; 65:4059–4066.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006; 8:R23.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012; 19:39–53.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2016; 23:830–843.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Lee ES, Han W, Kim MK, Kim J, Yoo TK, Lee MH, et al. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer. 2016; 16:430.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011; 129:607–616.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013; 105:1504–1511.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Grasic-Kuhar C, Bracko M, Zakotnik B. Risk factors for late relapse and death in patients with early breast cancer. Neoplasma. 2008; 55:416–420.
18. Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K. Prognostic significance of progesterone receptor expression in estrogen-receptor positive, HER2-negative, node-negative invasive breast cancer with a low Ki-67 labeling index. Clin Breast Cancer. 2017; 17:41–47.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008; 26:549–555.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010; 73:156–166.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126:529–537.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94:652–661.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59:56–66.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007; 25:1858–1869.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Varghese F, Wong J. Breast cancer in the elderly. Surg Clin North Am. 2018; 98:819–833.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol. 2018; 36:1941–1948.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Gnant M, Steger G, Greil R, Fitzal F, Mlineritsch B, Manfreda D, et al. Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial. Cancer Res. 2018; 78:GS3-01.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, et al. The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: a concise review. Cancer Treat Rev. 2019; 74:29–34.
![crossref](/image/icon/bnr_ref_cross.gif)
29. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30:1796–1804.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384:164–172.
![crossref](/image/icon/bnr_ref_cross.gif)